WO2000013664A1 - Drug preparations for treating sexual dysfunction - Google Patents
Drug preparations for treating sexual dysfunction Download PDFInfo
- Publication number
- WO2000013664A1 WO2000013664A1 PCT/US1999/020446 US9920446W WO0013664A1 WO 2000013664 A1 WO2000013664 A1 WO 2000013664A1 US 9920446 W US9920446 W US 9920446W WO 0013664 A1 WO0013664 A1 WO 0013664A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- drug
- negative charged
- nicotinic acid
- mixtures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- This invention relates to the preparation of a transdermal delivery system.
- the preparation is designed to deliver therapeutic levels of a drug which causes vasodilation, and optionally prostaglandin E : , to specific sites below the dermal level of the skin.
- the preparations address sexual dysfunction caused by impotency in males and vaginal dryness in females .
- thermosetting gels In U.S. Patent Nos. 4,474,751 and 4,478,822, drug delivery systems are described which utilize thermosetting gels; the unique feature of these systems is that both the gel transition temperature and/or the rigidity of the gel can be modified by adjusting the pH and/or the ionic strength, as well as by the concentration of the polymer.
- Ionic polysaccharides have been used in the application of drugs by controlled release. Such ionic polysaccharides as chitosan or sodium alginate are disclosed as useful in providing spherical agglomerates of water- insoluble drugs in the Journal of Pharmaceutical Sciences, Volume 78, Number 11, November 1989, Bodmeier et al . Calcium alginate gel formulations have also found use as a matrix material for the controlled release of herbicides, as disclosed in the Journal of Controlled Release, (1986), pages 229-233, Pfizer et al .
- a molded plastic mass composed of the reaction product of a hydrophilic colloid and a cross-linking agent such as a liquid polyol, also containing an organic liquid medium such as glycerin, is disclosed as useful in the controlled release of medication or other additives.
- the hydrophilic colloid can be carboxymethyl cellulose gum or a natural alginate gum which is cross-linked with a polyol. The cross- linking reaction is accelerated in the presence of aluminum and calcium salts.
- compositions are disclosed for the controlled release of pharmacological macromolecular compounds contained in a matrix of chitosan.
- Chitosan can be cross-linked utilizing aldehydes, epichlorohydrin and benzoquinone .
- U.S. Patent No. 4,795,642 there are disclosed gelatin-encapsulated, controlled-release compositions for release of pharmaceutical compositions, wherein the gelatin encloses a solid matrix formed by the cation- assisted gelation of a liquid filling composition incorporatin ⁇ a vegetable gum together with a pharmaceutically-active compound.
- the vegetable gums are disclosed as polysaccharide gums such as alginates which can be gelled utilizing a cationic gelling agent such as an alkaline earth metal cation. While the prior art is silent with respect to aqueous drug delivery vehicles and isotonicity thereof, osmotic drug delivery systems are disclosed in U.S. Patent No.
- 4,439,196 which utilize a multi-chamber compartment for holding osmotic agents, adjuvants, enzymes, drugs, pro-drugs, pesticides, and the like. These materials are enclosed by semipermeable membranes so as to allow the fluids within the chambers to diffuse into the environment into which the osmotic drug delivery system is in contact.
- the drug delivery device can be sized for oral ingestion, implantation, rectal, vaginal, or ocular insertion for delivery of a drug or other beneficial substance. Since this drug delivery device relies on the permeability of the semipermeable membranes to control the rate of delivery of the drug, the drugs or other pharmaceutical preparations by definition, are not isotonic with mammalian blood.
- male erectile dysfunction the persistent inability of a man to achieve or maintain an erection sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. See “Oral Sildenafil in the Treatment of Erectile Dysfunction", Netv England Journal of Medicine , 338:20:1397 (1998).
- There are numerous causes of male erectile dysfunction For example, it may be atonic, due to paralysis of the motor nerves without any evidence of lesions to the central nervous system, particularly the spinal cord. Alternatively, it could be psychic, and dependent on a mental problem or instability. Finally, it could be symptomatic, due to some other disorder, such as injury to nerves in the perineal region, by virtue of which the sensory portion of the erection reflex is blocked ou .
- U.S. Patent No. 5,583,144 discloses compositions for relieving erectile impotence in men which contain piperoxan in a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier commercially available gels, ointment and creams, such as the hydrogel, hydroxypropylmethylcellulose are optionally used.
- the patent does not address the importance of the rate of delivery to the site of action.
- U.S. Patent No. 5,256,652 discloses a topical composition which enhances the maintenance of penis erection and which contains a peripheral vasodilator, an absorption enhancer and, optionally, a vasocontrictor and an alpha receptor combined with a pharmacologically acceptable topical vehicle.
- the patent discloses that " [t.he problem with topically administered drugs is their limited penetration of the drug through the skin” and encourages the use of a skin penetration enhancer. See column 2, lines 59-65. There is no teaching or warning that the rate or amount of absorption may be too high to be effective as the result of drug entering fatty tissue.
- compositions for treating impotence which contain a vasodilator, a vasoconstrictor and an absorption enhancing agent in a pharmaceutically acceptable carrier.
- the patent also teaches that nicotinyl alcohol may be used as the vasodilator, but that side effects such as flushing and gastrointestinal disturbances may result.
- U.S. Patent No. 4,801,587 discloses a vasodilator or alpha-blocker in an ointment base.
- a drug carrier is only optionally used when necessary to increase absorption.
- the patent urges the importance of increasing absorption into the skin while not addressing the proper rate of absorption necessary to attain therapeutically effective amounts at the site of action.
- the delivery systems disclosed in the above references have lacked the sophistication necessary to deliver the drug at a rate which provides a therapeutically effective amount at the active site when needed and for an appropriate amount of time.
- the disclosed topical formulations are generally ot storage stable.
- sexual dysfunction is not limited to men.
- vaginal dryness caused by loss of normal vulval and vaginal secretions, particularly during sexual activity, resulting in difficulty with or an inability to achieve intercourse.
- therapies which address the problem of vaginal dryness. Though in mild cases, local hygiene and antipruritic ointments and creams may be beneficial, typically additional therapy will be necessary.
- Some currently available therapies involve treatment with hormone-based formulas containing either testosterone or glucocorticoids . Parnell, U.S. Patent No.
- U.S. Patent No. 4,347,237 discloses a vaginal suppository composed of a variety of different types of water soluble polyoxy alkylene polyol components .
- the formulations disclosed in the prior art are all deficient in that the delivery systems which they employ do not carefully control the rate of delivery of the active therapeutic agent which in turn can lead to adverse effects.
- currently used testosterone treatments can produce clitoral enlargement or other masculinization, and glucocorticoids when used for long periods of time carry a serious risk of producing atrophy and thinning of the epithelium.
- the present invention relates to the formation of gelled compositions and methods for using said gelled compositions in treating sexual dysfunction, including impotency or erectile dysfunction in males, and sexual dysfunction in females caused by vaginal dryness.
- the methods of the invention comprise topically applying to a specific site on the surface of an animal a therapeutically effective amount of a drug which causes vasodilation dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium, wherein the polymer matrix contains a negative charged polymer blended with a nonionic polymer, and wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:4 to 0.09, and the negative charged polymer is present in amounts of about 1.0% to about 3.5% by weight.
- the gelled composition contains prostaglandin E-,, in addition to the drug which causes vasodilation.
- a method for the treatment of erectile dysfunction in a male animal comprises topically applying to the surface of a penis a therapeutically effective amount of a drug which causes vasodilation, and optionally prostaglandin E, . , dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium; wherein the polymer matrix contains a negative charged polymer blended with a nonionic polymer; and wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:0.5 to 0.09 and the negative charged polymer is present in amounts of about 2.0% to about 3.5% by weight.
- a gelled composition for treating impotency comprises therapeutically effective amounts of a drug which causes vasodilation, and optionally prostaglandin E l r dispersed within a matrix containing a negative charged polymer blended with a nonionic polymer, wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:4 to 0.09 and the negative charged polymer is present in amounts of about 1.0% to about 3.5% by weight.
- a method for the treatment of erectile dysfunction in male animals comprises injecting into the corpora cavemosa a therapeutically effective amount of a drug which causes vasodilation, and optionally prostaglandin E x , dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium; wherein the polymer matrix contains a negative charged polymer blended with a nonionic polymer; and wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:4 to 0.09 and the negative charged polymer is present in amounts of about 1.0% to about 3.5% by weight .
- a method for the treatment of sexual dysfunction or vaginal dryness in a female animal comprises topically applying to the surface of a vagina a therapeutically effective amount of a drug which causes vasodilation, and optionally prostaglandin E x , dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium, and wherein the polymer matrix contains a negatively charged polymer blended with a nonionic polymer, and wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:4 to 0.09 and the negative charged polymer is present in amounts of about 1.0% to about 3.5% by weight.
- a gelled composition for treating vaginal dryness comprises therapeutically effective amounts of a drug which causes vasodilation, and optionally prostaglandin ⁇ x , dispersed within a matrix containing a negative charged polymer having a mean average molecular weight between about 650,000 and 800,000 blended with a nonionic polymer, wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:4 to 0.09 and the negative charged polymer is present in amounts of about 1.0% to about 3.5% by weight.
- an effective therapeutic level of a drug may be administered topically and transdermally delivered through the skin into various sites where the drug is therapeutically effective.
- the active drug must be suspended or entrapped in a specially designed polymer matrix containing a specific molar ratio of negatively charged polymers and a non-ionic polymer suspended or dissolved in water and solubilizers .
- This system is believed to form a matrix which microencapsulates, suspends, and/or entraps the active drug entity such that when it is administered, it is slowly released into the systemic circulatory system or muscular tissue providing a method of delivering an active drug to an affected site in the body through the skin.
- the molar ratio of the polymers present in the matrix is critical in this invention. It has been found that molar ratios of the negative charged polymer to the non- ionic polymer must be from 1:4 to 0.09, and preferably from 1:2.5 to 0.1, and most preferably from 1:0.4 to 0.2. For transdermal delivery of drugs, it has been found that ratios either higher or lower than these levels will result in a polymer shearing effect which produces unacceptable turbulence and air pockets in the composition with resulting loss of potency and efficacy. Furthermore, the solutions tend to separate and form distinct polymer layers when ionic molarity is not appropriate. While gels and other topical therapeutic compositions generally encounter problems with storage stability, the present invention demonstrates an unexpectedly superior storage stability.
- At least one of the polymers used to form the matrix of this invention must be sufficiently negatively charged to aid in the dispersion, encapsulation or solubilization of the drug.
- the viscosity and molecular weight of the negative charged polymer is also critical to the invention.
- at least one of the polymers of the invention must be a nonionic polymer.
- the viscosity and molecular weight of the nonionic polymer is also critical to the invention.
- Particularly preferred nonionic polymers which have a viscosity of about 1,500 for a 5% solution to about 5,500 for a 1% solution have been found to be suitable for forming a polymer matrix capable of transdermal drug delivery.
- nonionic polymers with viscosities below these ranges will result in an excessive rate of release leading to drug dispersion into fatty tissue, causing reduced efficacy, while requiring higher levels of drug with accompanying side effects.
- Using nonionic polymers with a viscosity above these ranges will result in solid materials which are unsuitable for transdermal drug delivery.
- viscosity refers to the intrinsic viscosity of a polymer in solution (the viscosity which the unassociated polymer molecules give to the solution) and is a function of the molecular weight and very easily measured. Intrinsic viscosity is commonly used for control purposes, and the values can be converted into molecular weight by calibration with osmotic pressure, light scattering, or sedimentation measurements.
- the viscosity measurements and ranges used herein were provided by Aqualon, a division of Hercules, Inc., in its product specifications for Natrosol ® (hydroxyethyl-csllulose) , and all were Brookfield viscosities measured at 25°C. It is well within the capabilities of an ordinarily skilled artisan to obtain and/or identify polymers within the ranges specified by the invention.
- Particularly preferred negative charged polymers which have mean average molecular weights below about 800,000 and preferably molecular weights between 650,000 to 800,000 have been found acceptable to form usable polymer matrixes for transdermal delivery. Polymers with average molecular weights between 700,000 and 775,000 are most preferred. Polymers having molecular weights above about 800,000 form solid gels in solution and are unable to serve as part of a transdermal delivery system. Furthermore, the polymers must be sterilizable and be stable during sterilization so that the polymer does not lose molecular weight once formulated into the final transdermal delivery form.
- Exemplary, non-limiting examples of compounds that may be used as a source of this molecular weight polymer include polysulfated glucosoglycans , glucosaminoglycans, and mucopolysaccharides, derivatives thereof and mixtures thereof.
- Particularly preferred mucopolysaccharides are chondroitin sulfate and hyaluronic acid salts.
- Exemplary hyaluronate salts include sodium, calcium, potassium and magnesium salts with hyaluronate sodium being most preferred.
- Hyaluronic acid occurs naturally in joint synovial fluid, where it plays a lubricating role, and may have biological activity as well.
- NAHA is a mucopolysaccharide, and may alternatively be referred to as glucosaminoglycan.
- the repeating unit of the hyaluronic acid molecule is a disaccharide consisting of D-glucuronic acid and N-acetyl-D-glucosamine . Because hyaluronic acid possesses a negative charge at neutral pH, it is soluble in water, where it forms highly viscous solutions.
- the D-glucuronic acid unit and N-acetyl-D- glucosamine unit are bonded through a glycosidic, beta (1-3) linkage, while each disaccharide unit is bonded to the next disaccharide unit through a beta (1-5) linkage.
- the (beta 1-4) linkages may be broken through hydrolysis with the enzyme hyaluronidase .
- hyaluronic acid A variety of substances, commonly referred to as hyaluronic acid, have been isolated by numerous methods from various tissue sources including umbilical cords, skin, vitreous humor, synovial fluid, tumors, hemolytic streptocci pigskin, rooster combs, and the walls of veins and arteries. It is also being synthesized artificially and by recombinant technology. Conventional methods for obtaining hyaluronic acid results with a product having differing properties and a wide range of viscosities.
- 2,585,546 to Hadian discloses an example of a method for obtaining hyaluronic acid and which involves extracting acetone- washed umbilical cords with a dilute salt solution, acidifying the resulting extract, removing the clot so formed, precipitating some hyaluronic acid with protein from the acidified extract with ammonium sulfate, agitating the liquid with pyridine, precipitating another fraction highly contaminated with protein, followed by more ammonium sulfate which forces some pyridine out of solution along with the high viscosity hyaluronic acid.
- the hyaluronic acid collects at the interface between the two liquid phases and may be separated by filtration, centrifugation or another usual procedure.
- a modification of this process involves the fractionation of the acidic salt extract from umbilical cords with alcohol and ammonium sulfate. Alcohol is added to the acidic salt extract, and the resulting precipitate is removed. Solid ammonium sulfate is added to the liquid until saturation and the solution forms two phases with a precipitate of hyaluronic acid at the interface.
- U.S. Patent No. 4,517,296 is directed to the preparation of hyaluronic acid in high yield from Streptococcus bacteria by fermenting the bacteria under anaerobic conditions in a CO, enriched growth medium, separating the bacteria from the resulting broth and isolating the hyaluronic acid from the remaining constituents of the broth. Separation of the microorganisms from the hyaluronic acid is facilitated by killing the bacteria with trichloroacetic acid. After removal of the bacteria cells and concentration of the higher molecular weight fermentation products, the hyaluronic acid is isolated and purified by precipitation, resuspension and reprecipitation.
- hyaluronic acid that exhibits excellent matrix formation according to the present invention is hyaluronate sodium having a mean or average molecular weight between 650,000 - 800,000, preferably 700,000 - 775,000 with a high degree of purity, 95-105% free, and preferably at least 98% pure, from contamination of related mucopolysaccharides. Furthermore, this hyaluronic acid has a sulphated ash content of less than 15% and a protein content of less than 5%.
- usable base salts include those safe from animal and human use, such as sodium, potassium, calcium, and magnesium salts or the like.
- chondroitins are mucopolysaccharides comprising repeating units of D- glucuronic acid and N-acetyl-D-galactosamine . Chondroitin sulphates are important components of cartilage and bone and are excellent for preparing the polymer matrix herein.
- the negative charged polymers are generally present in the system in amounts which enable a semi -solid gel to be formed.
- gels are formed using amounts of about 1.0 to about 3.5% by weight with amounts of about 2.1 to about 2.5% by weight being preferred for use as a topical gel. Concentrations of negative charged polymer greater than 3.5% result in solids which are not suitable for pharmaceutical use.
- the solutions used to prepare the gels of the present invention may be prepared in a variety of ways. For example, the polymers may be dissolved in water and purified either separately or jointly and then the optional active drug added to the system.
- a particularly preferred procedure involves separately dissolving the nonionic polymer in water and centrifuging the material to form a solution and remove impurities. This may be conveniently done at rotation speeds of 2000 rp for times of about 30 minutes to about two hours .
- the negative charged polymer may be blended and stirred n water until it is dissolved. This process must be done while avoiding the formation of bubbles and while freeing the polymer of its electrostatic activity. Furthermore, the molecular weight of the polymer must not be significantly changed during processing and as such mild process conditions are required. Processing conditions of 400 - 3000 rpm for durations of 16 - 24 hours have been found acceptable to produce stable solutions or gels of the charged polymer.
- the drug may be added to the homogenous solution or gel separately once dissolved or disbursed in water. Emulsifiers, suspending agents and preservatives may then be added to this system.
- One particularly nonlimiting effective material for solubilizing water insoluble drugs is methoxypolyethylene glycol (MPEG) .
- the formulations may be used topically and also contain conventional pharmaceutically acceptable excipients well known to those skilled in the art, such as surfactants, suspending agents, emulsifiers osmotic enhancers, extenders and dilutants, pH modifiers as well as fragrances, colors, flavors and other additives.
- conventional pharmaceutically acceptable excipients well known to those skilled in the art, such as surfactants, suspending agents, emulsifiers osmotic enhancers, extenders and dilutants, pH modifiers as well as fragrances, colors, flavors and other additives.
- genital area refers to the general area of a male or female which contains or surrounds the v genital ⁇ organs .
- the compositions may be directly applied anywhere on the epidermis of the genital area.
- the composition should be applied to the epidermis of the penis and testicles.
- the composition should be applied directly to the vagina.
- the active drug agents may be blended with the aqueous polymer matrix at the time of manufacture. As such, the drug when in the form of a water-soluble solid is simply diluted with sterilized water or polymer matrix solution and prepared in gel form.
- the dosage system can be formed with or without the use of pharmaceutically acceptable preservatives.
- a significant advantage of the dosage form of the present system relates to its ability to allow the drug to slowly diffuse through tissue when administered thus allowing for an effective therapeutic dose to be present for long periods of time, i.e., 15 minutes to several hours.
- reference to therapeutically effective dose does not necessarily relate to conventional dosage levels, but does relate to drug levels that achieve an effective therapeutic level at the dose employed, which may be the same level but not at the same frequency of administration previously required for drugs taken orally or by injection. This not only significantly reduces the number of doses required to achieve the same effect, but it also reduces costs, maintenance and health hazards associated with conventional treatment therapies.
- Doses may vary from patient to patient depending on the type and severity of the condition being treated and the drug being administered. Generally, doses of 150 meg to 1000 meg may be administered with preferred doses using 200 to 500 meg of drug disbursed in the gelled matrix system. The total dosage of the gelled matrix with drug is usually 0.5 ml to 5 ml in volume.
- the drug which causes vasodilation is niacin
- the preferred amount of total composition in each dose will range between about 1 ml and 3 ml . in volume .
- vascular disturbances such as aortic aneurysm and atherosclerosis (e.g., Leriche's syndrome); neurogenic disorders (e.g., multiple sclerosis, spinal cord lesions, pituitary mifcroadenoma with hyperprolactinemia, and cardiovascular accident) ; drugs such as hypertensives, sedatives, tranquilizers , and amphetamines; and surgical procedures such as sympathectomy, prostatectomy and castration produce varying effects . Impotence is usually not induced by transurethral prostatectomy, whereas it almost always occurs after perineal prostatectomy. However, retrograde ejaculation is produced in the vast majority of men, irrespective of the type of prostatectomy.
- Pharmacological erection therapy is an effective method to treat male erectile dysfunction.
- the medications most commonly used have been papaverine hydrochloride, a smooth muscle relaxant , and phentolamine mesylate, an c.-adrenergic blocker.
- Recent data have suggested that prostaglandin E x either alone or in combination with papaverine produces an improved erectile response .
- prostaglandin E x is presently the single most effective agent for pharmacological erection therapy.
- the present invention contemplates using prostaglandin E x as a catalyst to be used in conjunction with a drug which causes vasodilation in cases in which the drug which causes vasodilation may not alone be effective.
- Prostaglandin E 1 is a physiological agent that is metabolized locally within the cavernous tissue and there appears to be a low incidence of corporeal fibrosis, priapism or systemic reactions associated with its use.
- Prostaglandin E x has also been found to be extremely effective as a single agent in several other studies. Liu et al . recently reported that prostaglandin E,_ is at least as effective as papaverine in increasing penile blood flow measured by duplex sonography. Prostaglandin E-_ has the advantage over papaverine of a slower onset, longer maintenance and less chance of priapism. Despite these advantages, however, prostaglandin E x is associated with a significant incidence of penile discomfort.
- Prostaglandin E-_ is a naturally occurring acidic lipid that is synthesized from fatty acid precursors by most mammalian tissues and has a variety of pharmacologic effects.
- Human seminal fluid is a rich source of prostaglandins, including PGE X and PGE 2 , and the total concentration of prostaglandins in ejaculate has been estimated to be approximately 100-200 mcg/mL .
- alprostadil PGE has been shown to cause dose-dependent smooth muscle relaxation in isolated corpus cavernosum and corpus spongiosum preparations.
- vasodilation has been demonstrated in isolated cavernosal artery segments that were pre-contracted with either norepinephrine or prostaglandin E 2 ⁇ .
- the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arterial inflow and expansion of the lacunar spaces within the corpora.
- Alprostadil is rapidly metabolized locally by enzymatic oxidation of the 15-hydroxyl group to 15-keto- PGE- L .
- the enzyme catalyzing this process has been isolated from many tissues in the lower genitourinary tract including the urethra, prostate, and corpus cavernosum.
- 15-keto-PGE j ⁇ retains little (1-2%) of the biological activity of PGE X .
- 15-keto-PGE x is rapidly reduced at the C 13 -C 14 position to form the most abundant metabolite in plasma, 13 , 14-dihydro, 15-keto PGE._ (DKH- PGE X ) , which is biologically inactive. The majority of DKH-PGE !
- the drug which causes vasodilation may be any pharmaceutically acceptable substance which causes any vasodilation either directly or indirectly when administered to an animal.
- the drug which causes vasodilation may be any drug which is classified, without limitation, in one of the following categories: vasodilators, nitrovasodilators , ACE inhibitors, angiotensin receptor antagonists, phosphodiesterase inhibitors, direct vasodilators, adrenergic receptor antagonists, calcium channel blocking drugs, alpha blockers, beta blockers, lympathomimetics , vitamins, organic nitrates, serotonin receptor blocking agents, angina blocking agents, other anti-hypertensive agents, cardiac stimulating agents, agents which improve renal vascular function, sympathomimetic amine and mixtures thereof .
- Particularly preferred drugs which cause vasodilation include, without limitation, any of the following: niacin, nitroglycerine, nilatrin hydrochloride, pentoxyphylene , phenoxybenzamine , dichlophenac, papaverine, hydralazine, hydrazaline, hydrochloride, hydrochlorothiazide, sodiumnitroprusside, isoxaprine hydrochloride, epoprostenol sodium, nylidrin hydrochloride, tolazoline hydrochloride, nicotinyl alcohol, phentolamine, phentolamine mesylate, pentolamine hydrochloride, yohimbine, thymoxamine imipramine, verapamil, isoxsuprine, naftidrofuryl , tolazoline, hydroisosorbide, dibenamine , dinitrate, captopril, enalapril, enala
- the drug which causes vasodilation is selected from the group consisting of niacin, nicotinic acid, nicotinic acid precursors, esters of nicotinic acid and mixtures thereof.
- the formulations of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known in the pharmaceutical art .
- an effective but nontoxic amount of the system is employed in treatment .
- the dose regimen for administering drugs or treating various conditions, such as pain as described above, is selected in accordance with a variety of factors including the type, age, weight, sex, and medical condition of the subject, the severity of the pain, the route of administration and the particular complex or combination of drugs employed. Determination of the proper dose for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum doses of the compound. Thereafter, the dose is increased by small increments until the optimum effect under the circumstances is reached.
- the total daily dosage may be divided and administered in portions during the day if desired.
- amounts of drug may vary from 0.0001% to about 75% by weight of the system when using topically with 0.5 to 5 ml concentrations and preferably in 1 to 3 ml amounts .
- formulations of this invention are particularly useful in the administration of drugs that could be previously administered only by injection.
- the transdermal delivery system described herein offers a major alternative especially for those individuals who have a history of undesirable side- effects associated with irritation and/or pain from the injection. Also for those patients who have already suffered damage, the transdermal preparations described herein present a new way of providing effective treatment and relief of painful symptoms.
- Female sexual dysfunction is generally caused by vaginal dryness. Women most susceptible to vaginal dryness include menopausal women, women undergoing radiation therapy, and women suffering from an autoimmune disease. However, vaginal dryness is not limited to such women, and may be caused by numerous factors, many of which may be as yet unidentified. Because female sexual dysfunction has traditionally received significantly less attention than male sexual dysfunction, there is little literature available on the subject.
- vaginal dryness is directly caused by vulvar dystrophy.
- the vulvar dystrophies are a common group of disorders in which various parts of the vulva atrophy or become dystrophic. While the vulvar dystrophies are common after menopause, they can occur at any time of life, even during childhood. Treatment is often unsatisfactory. See Horrobin, U.S. Patent No. 5,380,757. Local hygiene and antipruritic ointments and creams may be beneficial but topical preparations containing either glucocorticoids or testosterone, the male sex hormone, are usually required.
- Vaginal dryness can also be caused by pharmacological influences, for example, as a common side effect of many medications, including diuretics, antiarthritics and antidepressants .
- synthetic lubricants or synthetic moisturizers are prescribed for such situations, with limited effectiveness.
- the methods and compositions of the present invention contemplate the treatment of female sexual dysfunction in its broadest manifestations.
- the drug delivery system which the present invention embodies is ideally suited for the topical application of formulations capable of containing an active agent and releasing said agent in a controlled manner to achieve efficacious transdermal drug delivery without the side effects which may accompany the same agent when used with delivery systems disclosed in the prior art.
- the formulations of the invention may be applied to the surface of the vagina, so that a therapeutically effective amount of the drug for treating vaginal dryness is released in a controlled manner, and thus the drug penetrates the exterior layers of the vagina to relieve said vaginal dryness .
- the transdermal polymer matrix must contain a non- ionic polymer which facilitates in retarding the absorption of the active drug through the skin and delays or slows down in animals natural absorption of the negatively charged polymer.
- non-ionic polymers are necessary to provide thorough penetration of skin layers including the epidermis, dermis and fatty tissue layers.
- Particularly preferred nonionic polymers are cellulose derivatives and particularly those selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof. These particular polymers have been found to possess exceptional ability to form sustained release matrix formulations when used in combination with a negative charged polymer. Such polymers are generally employed in amounts of about 0.1% to about 1.5% and preferably about 0.5 to about 1.4%. Amounts above about 1.5% result in the formation of a solid gel when used with the negative charged polymer. Amounts below about 0.1% have not been found suitable to prepare a storage stable product that has sustained drug release .
- a particularly preferred HEC concentration is about 0.2% to about 1.0% by weight of the matrix.
- a wide variety of other medicaments which may be administered topically may be used in the delivery system according to this invention.
- These drugs include, without limitation, papaverine hydrochloride, phentolamine mesylate and prostaglandin E l r nicotinic acid, glycerol, propylene glycol, testosterone, testosterone propionate, glucocorticoids, hydrocortisone , gamma- linolenic acid (GLA) , dihomo-gamma-linolenic acid (DGLA) , Yerba Santa extract and mixtures thereof.
- GLA gamma- linolenic acid
- DGLA dihomo-gamma-linolenic acid
- Yerba Santa extract and mixtures thereof.
- One particular criteria of the drug is that they must be solubilized in the polymer matrix solution in order to be topically administered.
- compositions and methods of the present invention are particularly helpful to invidiuals using a medication for preventing or treating hypertension (e.g. , an antihypertensive medication) or heart disease, such as organic nitrates. While many currently available therapies for treating erectile dysfunction are contraindicated for individuals on such medications, the present invention is not so contraindicated. For example, oral admistration of sildenafil citrate
- VIAGRA ® siagra citrate
- compositions and methods of the present invention may be used by individuals who are currently taking organic nitrates or other drugs which may be used to treat hypertension or heart disease.
- the dosing of the therapy must be carefully regulated to avoid adverse effects, thus typically preventing a therapeutically effective amount of drug from being delivered to the active site. Accordingly, there is a large group of individuals for whom the present invention may be the only safe and effective therapy.
- male erectile dysfunction there are numerous causes of male erectile dysfunction. For example, it may be atonic, due to paralysis of the motor nerves without any evidence of lesions to the central nervous system, particularly the spinal cord. Alternatively, it could be psychic, and dependent on a mental problem or instability. Finally, it could be symptomatic, due to some other disorder, such as injury to nerves in the perineal region, by virtue of which the sensory portion of the erection reflex is blocked out.
- the compositions and methods of the present invention act independently of the particular cause.
- impotence may be of varying degrees.
- impotence may be absolute, involving all sexual modalities; or total, affecting all sexual function, though not necessarily libido; or partial, affecting the rigidity or duration of the erection.
- the cause of impotence is organic, due to structural changes, disease or some demonstrable functional impairment anywhere in the sexual system, psychogenic due to old age or sexual satiation, the result is the same; at least partial inability to engage in sexual activity due to the lack of an adequate erection.
- the compositions and methods of the present invention act independently of these varying degrees .
- This example demonstrates the formation of a transdermal preparation of alprostadil.
- the dosage range for the drug is between 2-3 ml.
- NAHA Sodium hyaluronate
- HEC Hydroxyethyl cellulose
- MPEG Methoxypolyethylene glycol
- the final mixture is clear with a slight tint following 15 to 20 hours of further mixing at 2000 rpm.
- the final product should be transferred, using aseptic techniques, to 1-5 ml tubes.
- approximately 2 ml of matrix is applied to the exterior surface of the penis 10 to 15 minutes before intercourse.
- approximately 2 ml may be infused into the urethra 10 to 15 minutes before intercourse. Either technique results in the formation of an erection.
- Example 2 A transdermal preparation of Alprostadil is prepared in the manner of Example 1 with the following components :
- NAHA Sodium hyaluronate
- HEC Hydroxyethyl cellulose
- MPEG Methoxypolyethylene glycol
- the dosage range for the drug is between 2-3 ml. Examp 1 e 3
- a transdermal preparation of Alprostadil is prepared in the manner of Example 1 with the following components:
- HEC Hydroxyethyl cellulose
- the dosage range for the drug is between 2-3 ml.
- a transdermal preparation of Alprostadil, prostaglandin-E 1 - ⁇ -cyclodextrin complex (a water-soluble source of prostaglandin E ⁇ ) , formula is prepared in the following manner.
- a transdermal preparation of Alprostadil (prostaglandin E x ) formula was prepared in the following manner . First, 20 ml of prostaglandin E ⁇ was dissolved in
- a transdermal preparation of Alprostadil (0.4%) formula is prepared in the following manner.
- a mixture is prepared by dissolving 14.7 grams of Sodium Hyaluronate (NAHA) in 350 ml of water, then stirring the resulting solution at 1800 rpm initially, reducing to 800 rpm and stirring for 2 hours, and then stirring at a low speed overnight. To the resulting mixture is added a mixture of 75 ml MPEG, and then 12.5 ml of benzyl alcohol, stirred for 30 minutes, is added. The resulting mixture is then stirred for 2 hours .
- NAHA Sodium Hyaluronate
- a solution is prepared by adding 3.5 g (0.7)% HEC to 75 ml of water and stirring for 35 minutes. The resulting solution is then added to the above formed mixture and stirred at a moderate speed overnight to form an NAHA/HEC polymer matrix.
- prostaglandin E x is added to 10 ml of the NAHA/HEC polymer matrix. The mixture is stirred for 2 hours. 0.5 to 0.75 ml of the resulting gel is loaded into syringes and stored in a refrigerator.
- Example 7 A topical gel formula for treating vaginal dryness is prepared in the manner of Example 6 by using a mixture of nicotinic acid and glycerol in place of prostaglandin E x .
- a topical gel formula for treating vaginal dryness is prepared in the manner of Example 6 by using a steroid, such as testosterone, in place of prostaglandin
- a transdermal preparation of Alprostadil (0.4%) formula (Batch Size 1000 ml) is prepared in the following manner .
- a mixture is prepared by dissolving 24 grams of (2.4%) Sodium Hyaluronate (NAHA) in 710 ml of water, mixing at a high speed for two hours or until clear, then reducing speed to 200-500 rpm and continuing to stir for 24 hours.
- NAHA Sodium Hyaluronate
- a solution is prepared by adding 5 grams HEC powder to 200 ml of water and stirring at a high speed
- EXAMPLE 10 A transdermal preparation of Alprostadil and Niacin formula (Batch Size 1000 ml) is prepared in the following manner .
- a mixture is prepared by dissolving 24 grams of (2.4%) Sodium Hyaluronate (NAHA) in 710 ml of water, mixing the resulting solution at 2000 rpm for two hours or until clear, then reducing speed to 200-500 rpm and continuing mixing for 24 hours.
- NAHA Sodium Hyaluronate
- a solution is prepared by adding 5 grams HEC powder to 200 ml of water and stirring for 35 minutes. The resulting solution is added to the above formed mixture and mixed for 24 hours. To this solution, 5 grams of Niacin (5%) is added and mixed for 24 hours.
- a transdermal preparation of Alprostadil (Prostaglandin E x ) formula is prepared in the following manner.
- a mixture is prepared by dissolving 24 grams of (2.4%) Sodium Hyaluronate (NAHA) in 710 ml, mixing the resulting solution at 2000 rpm for 2 hours or until clear, then reducing speed to 200-500 rpm and continuing mixing for 24 hours.
- NAHA Sodium Hyaluronate
- a solution is prepared by adding 5 grams of HEC powder to 200 ml water, mixing at 2000-2500 rpm for 35 minutes. The resulting solution is then added to the above formed mixture and mixed for 24 hours.
- a solution is prepared by slowly adding 1 gram of Alprostadil (Prostaglandin E to 80 ml MPEG and mixing at 600 rpm until fully dissolved but at least for 5 hours, then mixing at 300 rpm for 12 hours.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14155399A IL141553A0 (en) | 1998-09-08 | 1999-09-08 | Drug preparations for treating sexual dysfunction |
CA002342769A CA2342769A1 (en) | 1998-09-08 | 1999-09-08 | Drug preparations for treating sexual dysfunction |
EP99945548A EP1112061A1 (en) | 1998-09-08 | 1999-09-08 | Drug preparations for treating sexual dysfunction |
AU58129/99A AU773144B2 (en) | 1998-09-08 | 1999-09-08 | Drug preparations for treating sexual dysfunction |
MXPA01002180A MXPA01002180A (en) | 1998-09-08 | 1999-09-08 | Drug preparations for treating sexual dysfunction. |
JP2000568473A JP2002524408A (en) | 1998-09-08 | 1999-09-08 | Formulations for treating sexual dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/148,986 | 1998-09-08 | ||
US09/148,986 US6251436B1 (en) | 1995-09-29 | 1998-09-08 | Drug preparations for treating sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000013664A1 true WO2000013664A1 (en) | 2000-03-16 |
Family
ID=22528310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/020446 WO2000013664A1 (en) | 1998-09-08 | 1999-09-08 | Drug preparations for treating sexual dysfunction |
Country Status (9)
Country | Link |
---|---|
US (2) | US6251436B1 (en) |
EP (1) | EP1112061A1 (en) |
JP (1) | JP2002524408A (en) |
AU (1) | AU773144B2 (en) |
CA (1) | CA2342769A1 (en) |
IL (1) | IL141553A0 (en) |
MX (1) | MXPA01002180A (en) |
WO (1) | WO2000013664A1 (en) |
ZA (1) | ZA200101659B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000059491A2 (en) * | 1999-04-06 | 2000-10-12 | Zonagen, Inc. | Methods for modulating the human sexual response |
WO2002043807A2 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
WO2003088880A2 (en) * | 2002-04-16 | 2003-10-30 | Futura Medical Developments Limited | Condom |
WO2004011029A2 (en) * | 2002-07-26 | 2004-02-05 | Adams Kenneth W | Pharmaceutical compositions for penis enlargement |
WO2004084861A2 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Angiogenesis promotion by prostaglandin compositions and methods |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
EP2983717A4 (en) * | 2013-04-10 | 2016-04-13 | Glycobiosciences Inc | Topical nutraceutical composition |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
EP2637730A4 (en) * | 2010-11-12 | 2016-07-20 | Univ Utah Res Found | Intravaginal devices for controlled delivery of lubricants |
AU2017101856B4 (en) * | 2017-05-02 | 2021-08-05 | Oates & Family Pty Ltd | Procedure for Penile Girth Enhancement |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US6387407B1 (en) * | 1995-09-29 | 2002-05-14 | L.A.M. Pharmaceutical Corporation | Topical drug preparations |
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
AU5403499A (en) * | 1998-08-26 | 2000-03-21 | Queen's University At Kingston | Methods for remodeling neuronal and cardiovascular pathways |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
US6702733B1 (en) | 1999-07-01 | 2004-03-09 | 40 J's Llc | Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds |
US6650943B1 (en) | 2000-04-07 | 2003-11-18 | Advanced Bionics Corporation | Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction |
EP1284653B1 (en) * | 2000-05-09 | 2007-11-28 | Nitromed, Inc. | Infrared thermography and treatment of sexual dysfunctions |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
US20090024417A1 (en) * | 2001-03-26 | 2009-01-22 | Marks Richard D | Electronic medical record system |
US6885895B1 (en) | 2001-04-26 | 2005-04-26 | Advanced Bionics Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
US20050240229A1 (en) * | 2001-04-26 | 2005-10-27 | Whitehurst Tood K | Methods and systems for stimulation as a therapy for erectile dysfunction |
KR20120058618A (en) * | 2003-01-31 | 2012-06-07 | 다이이찌 산쿄 가부시키가이샤 | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
ITMI20031428A1 (en) * | 2003-07-11 | 2005-01-12 | Indena Spa | COMBINATIONS OF VASOACTIVE AGENTS AND THEIR USE FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS |
US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
PL1750766T3 (en) | 2004-05-11 | 2013-12-31 | Eb Ip Lybrido B V | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
US20060083724A1 (en) * | 2004-10-01 | 2006-04-20 | Hilst Todd W | Compositions for the treatment of femal sexual dysfunction |
US7619008B2 (en) * | 2004-11-12 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Xylitol for treatment of vaginal infections |
US20060127483A1 (en) * | 2004-12-10 | 2006-06-15 | Alan Drizen | Topical drug delivery system |
US20060217443A1 (en) * | 2005-03-28 | 2006-09-28 | Kimberly-Clark Worldwide, Inc. | Method for preventing and/or treating vaginal and vulval infections |
JP5148296B2 (en) * | 2005-06-27 | 2013-02-20 | 第一三共株式会社 | Angiotensin II receptor antagonist and pharmaceutical composition containing calcium antagonist |
US7786176B2 (en) * | 2005-07-29 | 2010-08-31 | Kimberly-Clark Worldwide, Inc. | Vaginal treatment composition containing xylitol |
ITMI20051777A1 (en) * | 2005-09-23 | 2007-03-24 | Pharmaproducts Uk Ltd | COLOSSUS-BASED COMPOSITIONS FOR VAGINAL DRYING TREATMENT |
EA012754B1 (en) | 2005-10-12 | 2009-12-30 | Юнимед Фармасьютикалз Ллк | Improved testosterone gel and method of use |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
WO2007070067A1 (en) * | 2005-12-16 | 2007-06-21 | Lyle Corporate Development, Inc. | Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen |
KR100845942B1 (en) | 2006-07-10 | 2008-07-11 | 주식회사태준제약 | Eye composition with reduced side effects and method of preparing the same |
TWI399223B (en) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | Solid dosage form of olmesartan medoxomil and amlodipine |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
US8770201B2 (en) * | 2007-10-26 | 2014-07-08 | Glycobiosciences Inc. | Condom with multifunctional coating |
US20100263675A1 (en) * | 2009-04-21 | 2010-10-21 | Ansell Healthcare Products Llc | Condom with Localized Active Agent |
US20090318510A1 (en) * | 2008-06-24 | 2009-12-24 | Glycobiosciences, Inc. | Topical drug delivery system |
US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
CA2896038C (en) * | 2015-07-03 | 2022-08-09 | Glycobiosciences Inc. | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0581581A2 (en) * | 1992-07-29 | 1994-02-02 | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. | Bioadhesive treatment compositions and methods of use |
WO1997011681A1 (en) * | 1995-09-29 | 1997-04-03 | Lam Pharmaceuticals Inc. | Sustained release delivery system and long acting narcotic analgesics and antagonists |
WO1998043614A1 (en) * | 1997-03-28 | 1998-10-08 | Lam Pharmaceuticals, Llc | Drug preparations for treating sexual dysfunction |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
WO1999030718A2 (en) * | 1997-12-18 | 1999-06-24 | Nathan Earl Scott | PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4521421A (en) | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
EP0266968A3 (en) | 1986-11-03 | 1988-08-24 | Gérard G. Cohen | Gelled ointment of vasodilating agent |
US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5017229A (en) | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US5527893A (en) | 1987-09-18 | 1996-06-18 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
IT1221826B (en) | 1988-06-08 | 1990-07-12 | Medico Harvey Srl Centro | PREPARED FOR TOPICAL USE FOR THE THERAPEUTIC TREATMENT OF IMPOTENTIA COEUNDI |
US5015474A (en) | 1988-11-22 | 1991-05-14 | Parnell Pharmaceuticals, Inc. | Composition for imparting moisture to a substrate |
US5059603A (en) | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
US5126348A (en) | 1989-09-26 | 1992-06-30 | The University Of Colorado Foundation, Inc. | Bioavailability enhancers |
US5190962A (en) | 1990-03-13 | 1993-03-02 | Sepracor, Inc. | Treating hypertension |
US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
GB9012469D0 (en) | 1990-06-05 | 1990-07-25 | Glaxo Group Ltd | Medicaments |
US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5399581A (en) | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
GB9113517D0 (en) | 1991-06-21 | 1991-08-07 | Procter & Gamble | Cleansing products |
DE69225053T2 (en) | 1991-07-09 | 1998-10-08 | Vitaphore Corp | COMPOSITIONS BASED ON COLLAGES FOR CONTROLLED RELEASE OF MEDICINAL PRODUCTS |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5264220A (en) | 1991-11-12 | 1993-11-23 | Long David M Jr | Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents |
GB9211229D0 (en) | 1992-05-27 | 1992-07-08 | Efamol Holdings | Fatty acid treatment |
US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
US5525357A (en) | 1992-08-24 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5333621A (en) | 1993-05-28 | 1994-08-02 | Eric Denzer | Condom with transdermal vasodilator |
US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
US5583144A (en) | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US6036977A (en) | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US5958427A (en) * | 1996-11-08 | 1999-09-28 | Salzman; Andrew L. | Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications |
AU2479099A (en) * | 1998-01-28 | 1999-08-16 | Seatrace Pharmaceuticals, Inc. | Topical vasodilatory gel composition and methods of use and production |
-
1998
- 1998-09-08 US US09/148,986 patent/US6251436B1/en not_active Expired - Lifetime
-
1999
- 1999-09-08 IL IL14155399A patent/IL141553A0/en unknown
- 1999-09-08 WO PCT/US1999/020446 patent/WO2000013664A1/en not_active Application Discontinuation
- 1999-09-08 JP JP2000568473A patent/JP2002524408A/en active Pending
- 1999-09-08 MX MXPA01002180A patent/MXPA01002180A/en unknown
- 1999-09-08 CA CA002342769A patent/CA2342769A1/en not_active Abandoned
- 1999-09-08 AU AU58129/99A patent/AU773144B2/en not_active Ceased
- 1999-09-08 EP EP99945548A patent/EP1112061A1/en not_active Withdrawn
-
2001
- 2001-02-28 ZA ZA200101659A patent/ZA200101659B/en unknown
- 2001-05-15 US US09/854,509 patent/US6514536B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0581581A2 (en) * | 1992-07-29 | 1994-02-02 | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. | Bioadhesive treatment compositions and methods of use |
WO1997011681A1 (en) * | 1995-09-29 | 1997-04-03 | Lam Pharmaceuticals Inc. | Sustained release delivery system and long acting narcotic analgesics and antagonists |
WO1998043614A1 (en) * | 1997-03-28 | 1998-10-08 | Lam Pharmaceuticals, Llc | Drug preparations for treating sexual dysfunction |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
WO1999030718A2 (en) * | 1997-12-18 | 1999-06-24 | Nathan Earl Scott | PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
WO2000059491A3 (en) * | 1999-04-06 | 2002-05-02 | Zonagen Inc | Methods for modulating the human sexual response |
WO2000059491A2 (en) * | 1999-04-06 | 2000-10-12 | Zonagen, Inc. | Methods for modulating the human sexual response |
US9675539B2 (en) | 2000-03-31 | 2017-06-13 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9579270B2 (en) | 2000-03-31 | 2017-02-28 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
WO2002043807A2 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
WO2002043807A3 (en) * | 2000-12-01 | 2003-08-14 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
WO2003088880A3 (en) * | 2002-04-16 | 2004-01-08 | Futura Medical Dev Ltd | Condom |
CN100409827C (en) * | 2002-04-16 | 2008-08-13 | 富图拉医药发展有限公司 | Condom |
WO2003088880A2 (en) * | 2002-04-16 | 2003-10-30 | Futura Medical Developments Limited | Condom |
US7671091B2 (en) | 2002-07-26 | 2010-03-02 | Adams Kenneth W | Penis enlargement |
WO2004011029A3 (en) * | 2002-07-26 | 2004-05-21 | Kenneth W Adams | Pharmaceutical compositions for penis enlargement |
WO2004011029A2 (en) * | 2002-07-26 | 2004-02-05 | Adams Kenneth W | Pharmaceutical compositions for penis enlargement |
WO2004084861A3 (en) * | 2003-03-21 | 2005-01-27 | Nexmed Holdings Inc | Angiogenesis promotion by prostaglandin compositions and methods |
WO2004084861A2 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Angiogenesis promotion by prostaglandin compositions and methods |
EP2637730A4 (en) * | 2010-11-12 | 2016-07-20 | Univ Utah Res Found | Intravaginal devices for controlled delivery of lubricants |
US9642795B2 (en) | 2010-11-12 | 2017-05-09 | The University Of Utah Research Foundation | Intravaginal devices for controlled delivery of lubricants |
US10350160B2 (en) | 2010-11-12 | 2019-07-16 | University Of Utah Research Foundation, The | Intravaginal devices for controlled delivery of lubricants |
EP2983717A4 (en) * | 2013-04-10 | 2016-04-13 | Glycobiosciences Inc | Topical nutraceutical composition |
AU2017101856B4 (en) * | 2017-05-02 | 2021-08-05 | Oates & Family Pty Ltd | Procedure for Penile Girth Enhancement |
Also Published As
Publication number | Publication date |
---|---|
US20010022975A1 (en) | 2001-09-20 |
ZA200101659B (en) | 2001-12-18 |
US6514536B2 (en) | 2003-02-04 |
JP2002524408A (en) | 2002-08-06 |
AU5812999A (en) | 2000-03-27 |
CA2342769A1 (en) | 2000-03-16 |
EP1112061A1 (en) | 2001-07-04 |
IL141553A0 (en) | 2002-03-10 |
MXPA01002180A (en) | 2003-03-27 |
US6251436B1 (en) | 2001-06-26 |
AU773144B2 (en) | 2004-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6251436B1 (en) | Drug preparations for treating sexual dysfunction | |
US6036977A (en) | Drug preparations for treating sexual dysfunction | |
EP0971694B1 (en) | Drug preparations for treating sexual dysfunction | |
US6346271B1 (en) | Topical drug preparations | |
JP4354528B2 (en) | Use of hyaluronic acid to treat interstitial cystitis | |
CA2295595A1 (en) | Improved methods and compositions for treating male erectile dysfunction | |
US6387407B1 (en) | Topical drug preparations | |
US6589990B1 (en) | Methods and compositions for misoprostol compound treatment of erectile dysfunction | |
US20030138494A1 (en) | Drug preparations for treating sexual dysfunction | |
WO1999030718A2 (en) | PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL | |
EP1824494A1 (en) | Topical drug delivery system | |
CA2390841A1 (en) | Drug preparations | |
JP2002522500A (en) | Therapeutic agent for female sexual dysfunction containing misoprostol and / or misoprostolic acid | |
TW200526229A (en) | External preparation for treating sexual dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 141553 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/01659 Country of ref document: ZA Ref document number: PA/a/2001/002180 Country of ref document: MX Ref document number: 200101659 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2342769 Country of ref document: CA Ref country code: CA Ref document number: 2342769 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 58129/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999945548 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 568473 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1999945548 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 58129/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999945548 Country of ref document: EP |